Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 1/20 | 0.51 |
| ▸ | ALPI | P09923 | 1/20 | 0.51 |
| ▸ | ALPG | P10696 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | TCF4 | P15884 | 1/20 | 0.48 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | MPO | P05164 | 1/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | AMY1A | P0DUB6 | 6/20 | 0.45 |
| ▸ | METAP2 | P50579 | 2/20 | 0.45 |
| ▸ | METAP1 | P53582 | 2/20 | 0.45 |
| ▸ | CBFB | Q13951 | 1/20 | 0.45 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16053859 | 0.86 | MTOR (0.43) | ALPLALPIALPGADORA3PTGS1 | |
| SCHEMBL12331846 | 0.80 | ADORA2A (0.64) | METAP2METAP1CBFBADORA2A | |
| SCHEMBL21769332 | 0.80 | CSNK1D (0.48) | KDRHRH4ADORA2A | |
| SCHEMBL25749256 | 0.79 | MEN1 (0.54) | MAPK1RXFP1HRH4 | |
| SCHEMBL2146355 | 0.79 | ALDH1A1 (0.56) | ADORA2A | |
| Hydrochloric Acid SCHEMBL20291496 | 0.79 | ADORA2A (0.62) | ADORA2A | |
| SCHEMBL28376156 | 0.79 | ALDH1A1 (0.61) | MAPK1HRH4BACE1 | |
| SCHEMBL16188967 | 0.78 | IDO1 (0.60) | ALPLALPIALPGIDO1TCF4 | |
| SCHEMBL28503804 | 0.78 | KDM4E (0.45) | ADORA3PTGS1MAPK1KDRRXFP1 | |
| SCHEMBL4239909 | 0.78 | IDO1 (0.46) | ALPLALPIALPGIDO1TCF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115286645-A | Tricyclic heterocyclic derivatives, pharmaceutical compositions and uses thereof | 南京雷正医药科技有限公司 | 2022-11-04 | — | — | CN | disclosed |
| CN-111205310-A | Heterocyclic fused pyrimidine derivative, and pharmaceutical composition and application thereof | 上海迪诺医药科技有限公司 | 2020-05-29 | — | — | CN | disclosed |
| US-9421213-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2016-08-23 | — | — | US | disclosed |
| US-20160074412-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2016-03-17 | — | — | US | disclosed |
| US-9155742-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2015-10-13 | — | — | US | disclosed |
| US-20150164908-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2015-06-18 | — | — | US | disclosed |
| US-8999997-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2015-04-07 | — | — | US | disclosed |
| EP-2579877-B1 | MORPHOLINO PYRIMIDINES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2014-08-13 | — | — | EP | disclosed |
| US-20140018364-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2014-01-16 | — | — | US | disclosed |
| US-8552004-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2013-10-08 | — | — | US | disclosed |
| EP-2579877-A1 | MORPHOLINO PYRIMIDINES AND THEIR USE IN THERAPY | AstraZeneca AB (SE) | 2013-04-17 | — | — | EP | disclosed |
| US-20130005725-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2013-01-03 | — | — | US | disclosed |
| US-8252802-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2012-08-28 | — | — | US | disclosed |
| WO-2011154737-A1 | MORPHOLINO PYRIMIDINES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2011-12-15 | — | — | WO | disclosed |
| US-20110306613-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150164908-A1 | Chemical Compounds | CYP2C19, ABCG2, CYP2C9 | ALPL 3806/4885ALPI 1171/4885ALPG 3740/4885 |
| US-20110306613-A1 | CHEMICAL COMPOUNDS | CYP2C19, ABCG2, CYP2C9 | ALPL 3806/4885ALPI 1171/4885ALPG 3740/4885 |
| US-20160074412-A1 | Chemical Compounds | CYP2C19, ABCG2, CYP2C9 | ALPL 3806/4885ALPI 1171/4885ALPG 3740/4885 |
| US-20130005725-A1 | CHEMICAL COMPOUNDS | CYP2C19, ABCG2, CYP2C9 | ALPL 3806/4885ALPI 1171/4885ALPG 3740/4885 |
| US-20140018364-A1 | CHEMICAL COMPOUNDS | CYP2C19, ABCG2, CYP2C9 | ALPL 3806/4885ALPI 1171/4885ALPG 3740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.